IL132895A0 - Pharmaceutical formulation of omeprazole - Google Patents

Pharmaceutical formulation of omeprazole

Info

Publication number
IL132895A0
IL132895A0 IL13289598A IL13289598A IL132895A0 IL 132895 A0 IL132895 A0 IL 132895A0 IL 13289598 A IL13289598 A IL 13289598A IL 13289598 A IL13289598 A IL 13289598A IL 132895 A0 IL132895 A0 IL 132895A0
Authority
IL
Israel
Prior art keywords
omeprazole
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
IL13289598A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132895(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL132895A0 publication Critical patent/IL132895A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13289598A 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole IL132895A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation
PCT/SE1998/000922 WO1998053803A1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole

Publications (1)

Publication Number Publication Date
IL132895A0 true IL132895A0 (en) 2001-03-19

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13289598A IL132895A0 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole

Country Status (41)

Country Link
US (1) US6090827A (ru)
EP (1) EP0984773B1 (ru)
JP (1) JP4649001B2 (ru)
KR (1) KR100540721B1 (ru)
CN (1) CN1123338C (ru)
AR (1) AR012698A1 (ru)
AT (1) ATE234078T1 (ru)
AU (1) AU722879B2 (ru)
BR (1) BR9809484A (ru)
CA (1) CA2290531C (ru)
CZ (1) CZ298972B6 (ru)
DE (1) DE69812089T2 (ru)
DK (1) DK0984773T3 (ru)
DZ (1) DZ2494A1 (ru)
EE (1) EE03903B1 (ru)
EG (1) EG24044A (ru)
ES (1) ES2195342T3 (ru)
HK (1) HK1025744A1 (ru)
HR (1) HRP980260B1 (ru)
HU (1) HU229154B1 (ru)
ID (1) ID24654A (ru)
IL (1) IL132895A0 (ru)
IS (1) IS2856B (ru)
MA (1) MA26497A1 (ru)
MY (1) MY122298A (ru)
NO (1) NO328100B1 (ru)
NZ (1) NZ500886A (ru)
PL (1) PL194634B1 (ru)
PT (1) PT984773E (ru)
RS (1) RS49629B (ru)
RU (1) RU2207121C2 (ru)
SA (1) SA98190304B1 (ru)
SE (1) SE9702000D0 (ru)
SI (1) SI0984773T1 (ru)
SK (1) SK286625B6 (ru)
TN (1) TNSN98068A1 (ru)
TR (1) TR199902890T2 (ru)
TW (1) TW575435B (ru)
UA (1) UA71541C2 (ru)
WO (1) WO1998053803A1 (ru)
ZA (1) ZA984178B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
ATE369857T1 (de) 1999-10-20 2007-09-15 Eisai R&D Man Co Ltd Methode zur stabilisierung von benzimidazol- verbindungen
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
EP1588708A4 (en) * 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1747800B1 (en) * 2005-07-29 2009-03-18 Rottapharm S.p.A. Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
KR101104349B1 (ko) * 2007-09-28 2012-01-16 주식회사 씨티씨바이오 에소메프라졸 함유 약학 조성물
EP2273985B1 (en) * 2008-03-28 2016-02-17 Ferrer Internacional, S.A. Capsule for the prevention of cardiovascular diseases
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021153525A1 (ja) 2020-01-27 2021-08-05 東和薬品株式会社 エソメプラゾール経口製剤およびその製造方法
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
KR100540721B1 (ko) 2006-01-10
TR199902890T2 (xx) 2000-02-21
EE9900540A (et) 2000-06-15
AR012698A1 (es) 2000-11-08
HUP0002182A3 (en) 2003-02-28
AU7680398A (en) 1998-12-30
SI0984773T1 (en) 2003-10-31
ID24654A (id) 2000-07-27
HUP0002182A2 (hu) 2002-05-29
CZ298972B6 (cs) 2008-03-26
BR9809484A (pt) 2000-06-20
EG24044A (en) 2008-04-13
DZ2494A1 (fr) 2003-01-25
RS49629B (sr) 2007-08-03
EE03903B1 (et) 2002-12-16
PT984773E (pt) 2003-07-31
AU722879B2 (en) 2000-08-10
CZ420299A3 (cs) 2000-05-17
JP2002500665A (ja) 2002-01-08
DE69812089D1 (de) 2003-04-17
SK159099A3 (en) 2000-06-12
RU2207121C2 (ru) 2003-06-27
MY122298A (en) 2006-04-29
WO1998053803A1 (en) 1998-12-03
CA2290531C (en) 2006-12-12
NZ500886A (en) 2001-11-30
ES2195342T3 (es) 2003-12-01
DE69812089T2 (de) 2004-03-04
PL337237A1 (en) 2000-08-14
NO328100B1 (no) 2009-12-07
IS2856B (is) 2013-11-15
IS5245A (is) 1999-11-11
KR20010013104A (ko) 2001-02-26
CN1123338C (zh) 2003-10-08
TNSN98068A1 (fr) 2005-03-15
JP4649001B2 (ja) 2011-03-09
EP0984773A1 (en) 2000-03-15
HU229154B1 (en) 2013-09-30
DK0984773T3 (da) 2003-07-07
TW575435B (en) 2004-02-11
ATE234078T1 (de) 2003-03-15
HK1025744A1 (en) 2000-11-24
HRP980260B1 (en) 2003-10-31
ZA984178B (en) 1998-11-30
NO995809D0 (no) 1999-11-26
SK286625B6 (sk) 2009-02-05
EP0984773B1 (en) 2003-03-12
SE9702000D0 (sv) 1997-05-28
PL194634B1 (pl) 2007-06-29
NO995809L (no) 2000-01-28
CA2290531A1 (en) 1998-12-03
UA71541C2 (ru) 2004-12-15
US6090827A (en) 2000-07-18
HRP980260A2 (en) 1999-02-28
MA26497A1 (fr) 2004-12-20
YU60899A (sh) 2002-06-19
SA98190304B1 (ar) 2006-10-11
CN1258217A (zh) 2000-06-28

Similar Documents

Publication Publication Date Title
EG24044A (en) pharmaceutical formulation of omeprazole
EP1030654A4 (en) PREPARATION OF OMEPRAZOLE
HUP0004534A3 (en) Pharmaceutical formulation containing olanzapine
GB9713149D0 (en) Pharmaceutical formulations
ZA982872B (en) Pharmaceutical formulation
AP9901623A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP0001243A3 (en) Nicotinamide derivatives and pharmaceutical compositions containing them
IL133420A0 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HUP0002324A3 (en) Benzimidazole derivatives and pharmaceutical compositions containing them
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
GB9700737D0 (en) Administration of drugs
GB9709739D0 (en) Pharmaceutical formulation
HUP0001010A3 (en) Benzimidazole derivatives and pharmaceutical compositions containing them
GB9818927D0 (en) Pharmaceutical formulation
GB9822333D0 (en) Pharmaceutical formulation
GB9817470D0 (en) Pharmaceutical formulation
GB9802617D0 (en) Pharmaceutical formulation
SI1124539T1 (en) Pharmaceutical formulation comprising omeprazole
HUP0004274A3 (en) Bispyrido-cycloheptane compounds and pharmaceutical compositions thereof
HUP0001584A3 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees